Sai Parenterals Q1FY27: consolidated PAT -40% QoQ, margins compress on subsidiary drag

Sai Parenterals' consolidated (primary) Q1 FY27 print was ₹178.7 Cr revenue and ₹7.9 Cr PAT (EPS ₹1.79), down 9.7% and 39.8% sequentially from ₹197.9 Cr revenue and ₹13.2 Cr PAT (EPS ₹4.02) in Q4 FY26. Reported YoY growth looks explosive (revenue +435%, PAT +460% versus a ₹33.4 Cr/₹1.4 Cr year-ago quarter) but that base predates the company's NSE/BSE listing on 2 April 2026, when it wasn't yet required to publish quarterly numbers — the comparison is not like-for-like and should not be read as underlying organic growth. On a sequential basis, which is the cleaner read here, the quarter was weak: both topline and profitability retreated from the prior quarter.

The margin story is the bigger flag. Consolidated net margin compressed to 4.4% from roughly 6.6-6.65% in Q4 FY26, and derived EBITDA margin (PBT + finance cost + depreciation, over revenue) came in near 15.3% — below the 17% EBITDA margin management guided for FY27 at the May 2026 concall. Basis divergence is material: standalone net margin was 15.8% (PAT ₹8.9 Cr on ₹52.8 Cr revenue, EPS ₹2.01), more than 11 points above the consolidated 4.4%, meaning the overseas/subsidiary book (Noumed Pharmaceuticals Australia and other step-down units) is diluting group profitability sharply — a gap readers comparing the two statements will notice.

The stock went into the print at ₹573.5, down 2.3% over the past month of trading.

We found no analyst consensus or brokerage preview specifically for Sai Parenterals (a small, recently-listed name; web search results conflated it with the separate, larger Sai Life Sciences), so vsStreet is unknown rather than assumed. Against management's own May-2026 guidance of ₹750 Cr FY27 revenue and 17% EBITDA margin, Q1's ₹178.7 Cr is close to but slightly below the ₹187.5 Cr quarterly run-rate implied by that target, and margin is running under the 17% goal — an early miss on the guidance pace management set out as confident and optimistic just one quarter ago. Management's own press release framed the print positively (revenue ₹182 Cr on a total-income basis, PAT ₹8 Cr, outlook 'neutral'), which is consistent with our figures but glosses over the sequential decline and margin compression.